McGill IBD logo
Donate

Roche | Protocol GA29144

Molecule: Etrolizumab- Anti-integrin/Adhesion given SC


Study title:
A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of etrolizumab as an induction and maintenance treatment for patients with moderately to severely active Crohn’s disease

Roche | Protocol GA29145

Open Label Extension to GA29144


Study Title:
An open-label extension and safety monitoring study of patients with moderately to severely active Crohn’s disease previously enrolled in the etrolizumab Phase III Protocol GA29144

 

Janssen | Protocol CNTO1959CRD3001

Molecule: Guselkumab-Antil-IL 23 (IV induction-SC maintenance) compared with placebo and active control (ustekinumab)


Study title:
A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn’s Disease.

Abbvie | Protocol M15-991, M16-006

Molecule: Risankizumab-Anti-IL 23-IV induction


Study Title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn’s Disease.

Abbvie | Protocol M16-000

Molecule: Risakizumab-52 week maintenance & Open Label Extension to M15-991 or M16-006. SC injections +/- IV rescue


Study Title:
A Multicenter Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn’s Disease Who Responded to Induction Treatment in M16-006 or M15-991.

 

Abbvie | Protocol M14-431

Molecule: Upadacitinib (ABT-494)-Oral Jak inhibitor


Study Title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy

 

Abbvie | Protocol M14-430

Molecule: LTE study-Upadacitinib (ABT-494)-Oral Jak inhibitor


Study Title:
A Multicenter, Randomized, Double-Blind, Placebo Controlled Maintenance and Long Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn’s Disease who completed the M14-431 or M14-433 Studies.

 

Abbvie | Protocol M14-433

Molecule: Upadacitinib (ABT-494)-Oral Jak inhibitor


Study Title:

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn’s Disease who have Inadequately Responded to or are Intolerant to Conventional Therapies and/or Biologic therapies.

Takeda / Protocol Cx601-0303 (Pending Approval)


Study Title: A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn’s Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks

Bristol-Myers Squibb Protocol: IM011023 (Pending Approval)


Study Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn’s Disease

Abbvie Protocol: M20-259 (Pending Approval)


Study Title: A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects With Moderate to Severe Crohn’s Disease Who Have Failed Anti-TNF therapy

Arena | Protocol APD334-202 (Pending Approval)

Molecule: Etrasimod (orally administered, selective, synthetic sphingosine 1-phosphate (S1P) receptor 1, 4, 5 modulator)


Study Title:

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects With Moderately to Severely Active Crohn’s Disease.

 

Sponsor Montreal Health Institute Protocol: MHICC-2019-001 (Pending Approval)


Study Title: Evaluation of the response of itraconazole and terbinafine therapy in subjects with Crohn’s disease not responding adequately to current therapy (CD-IT)

Your donations contribute to the delivery of specialized and quality care to people with inflammatory bowel disease (IBD) in Quebec.

Your generosity benefits the IBD clinics at the Montreal General Hospital, the Montreal Children's Hospital and the Jewish General Hospital.

Donate